PBAC's latest decision on Upadacitinib: Recommended with restriction (2023). Considered for Continuing treatment of severe active rheumatoid arthritis in adults who have demonstrated an adequate response to prior PBS-subsidised biological medicine therapy.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
10
first 2019
Submissions
10
2019 → 2023
Eligible population
Adults aged ≥18 years with severe active rheumatoid arthritis who have received upadacitinib as their most recent course of PBS-subsidised biological medicine treatment and have demonstrated an adequate response, treated by a rheumatologist or clinical immunologist with expertise in rheumatoid arthritis management.
Therapy area
Rheumatology
Line of therapy
Any
Evidence base
Other
Economic model
Not modelled
ICER note
This is an administrative submission requesting amendment to authority levels for an already-listed medicine; no new economic evaluation was conducted.
ICER (historical)
$75k/QALY–$95k/QALY in an earlier submission (2021) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Nov 2019: Noted · Authority Required
Nov 2019: Recommended with restriction · Authority Required
Nov 2020: Noted · Restricted
Mar 2021: Recommended with restriction · Authority Required
Mar 2021: Recommended with restriction · Authority Required